Silihan lan utang jangka dawa perusahaan pluri-biotech.com (PLUR)

Pluri Inc. (PLUR) is a pioneer in cell therapy, developing biologics from placental tissues using 3D cultivation for muscle regeneration. This large-scale living tissue synthesis technology effectively combats radiation exposure and inflammation. The market value dynamics of the asset with the 0.00 indicator are illustrated below. Growth prospects rely on the transition to commercial licensing and cost optimization within metabolic programs.

This metric reflects the total volume of Pluri Inc. (PLUR) obligations with a maturity of more than one year, allowing for an assessment of the credit structure's stability and the cost of capital servicing. By analyzing changes in the company's long-term debt, an investor determines the firm's financial cushion, which is critically important for the biotechnology sector amid geopolitical instability in the Middle East and the risks of supply chain disruptions.